Search - tctmd.com

Displaying 21 - 40 of 202

Sort: Relevancy | Date

TCTMD’s Top 10 Most Popular Stories for October 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2018

October 31, 2018

Long-term Risk Factor Control Linked to Survival in COURAGE Substudy

News Daily News

Long-term Risk Factor Control Linked to Survival in COURAGE Substudy

Yael L. Maxwell

October 30, 2018

Final Phase III Bempedoic Acid Trial Proves Positive for LDL-Lowering

News Daily News

Final Phase III Bempedoic Acid Trial Proves Positive for LDL-Lowering

October 29, 2018

Patients With Schizophrenia Reap Gains From CV Meds After MI

News Daily News

Patients With Schizophrenia Reap Gains From CV Meds After MI

October 24, 2018

Coronary CTA for Suspected CAD Shows Advantages in Predicting Hard Outcomes Over 10 Years

News Daily News

Coronary CTA for Suspected CAD Shows Advantages in Predicting Hard Outcomes Over 10 Years

Yael L. Maxwell

October 23, 2018

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

News Features

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

October 22, 2018

Bariatric Surgery Reduces Hard CVD Events in Obese Patients With Type 2 Diabetes

News Daily News

Bariatric Surgery Reduces Hard CVD Events in Obese Patients With Type 2 Diabetes

Michael O'Riordan

October 18, 2018

Post-MI Beta-blocker Use Dropped During Metoprolol ER Shortage, but Outcomes Unaffected

News Daily News

Post-MI Beta-blocker Use Dropped During Metoprolol ER Shortage, but Outcomes Unaffected

October 15, 2018

Gender Gap May Be Narrowing in ACS Patients, With Mortality Advantage for Elderly Women

News Daily News

Gender Gap May Be Narrowing in ACS Patients, With Mortality Advantage for Elderly Women

October 12, 2018

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

News Daily News

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

October 12, 2018

Statin Preloading Benefit More Pronounced in STEMI Patients: SECURE-PCI

News Conference News TCT 2018

Statin Preloading Benefit More Pronounced in STEMI Patients: SECURE-PCI

Michael O'Riordan

October 05, 2018

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

News Daily News

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

October 03, 2018

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

News Conference News TCT 2018

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

Michael O'Riordan

October 02, 2018

TCTMD’s Top 10 Most Popular Stories for September 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2018

October 02, 2018

CorMicA Offers Glimmer of Hope for Testing, Treating Angina Without Obstructive CAD

News Conference News TCT 2018

CorMicA Offers Glimmer of Hope for Testing, Treating Angina Without Obstructive CAD

September 26, 2018

Even With PSP, Bioresorbable Scaffold Falls Short in ABSORB-COMPARE and ABSORB IV Trials

News Conference News TCT 2018

Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials

Michael O'Riordan

September 25, 2018

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

News Conference News TCT 2018

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Michael O'Riordan

September 24, 2018

Next Steps With NIRS: Lipid-Rich Plaque Study Shows Promise Identifying High-Risk Patients, Plaques

News Conference News TCT 2018

Next Steps With NIRS: Lipid-Rich Plaque Study Shows Promise Identifying High-Risk Patients, Plaques

Yael L. Maxwell

September 24, 2018

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

News Conference News TCT 2018

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

September 24, 2018

EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent

Presentation TCT 2018

EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent

Presenter: Dominick J. Angiolillo, Neal S. Kleiman, Ajay J. Kirtane

September 24, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.